PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30845975-8	2019	In contrast, the bortezomib/birinapant regimen upregulated TRAF3, downregulated TRAF2, and diminished p52 processing and BCL-XL expression, consistent with disruption of the non-canonical NF-kappaB pathway.	birinapant	28-38	TNF receptor associated factor 2	Homo sapiens	80-85	
30845975-9	2019	TRAF3 knockdown, ectopic TRAF2, or BCL-XL expression significantly diminished birinapant/bortezomib toxicity.	birinapant	78-88	TNF receptor associated factor 2	Homo sapiens	25-30	
24563541-0	2014	Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-kappaB activation, and is active in patient-derived xenograft models.	birinapant	0-10	TNF receptor associated factor 2	Homo sapiens	55-60	
24563541-0	2014	Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-kappaB activation, and is active in patient-derived xenograft models.	birinapant	12-19	TNF receptor associated factor 2	Homo sapiens	55-60	
24563541-8	2014	Birinapant preferentially targeted the TRAF2-associated cIAP1 and cIAP2 with subsequent inhibition of TNF-induced NF-kappaB activation.	birinapant	0-10	TNF receptor associated factor 2	Homo sapiens	39-44